5-fluorouracil + BCG + doxorubicin + cyclophosphamide

This is a multi-agent combination chemotherapy regimen composed of four agents: - 5-fluorouracil (an antimetabolite that inhibits thymidylate synthase, disrupting DNA synthesis) - Bacillus Calmette–Guérin (BCG, an immunotherapy agent used primarily in bladder cancer to stimulate the immune response) - Doxorubicin (an anthracycline antibiotic that intercalates DNA and inhibits topoisomerase II, leading to DNA damage and apoptosis) - Cyclophosphamide (an alkylating agent that cross-links DNA strands, inhibiting cell division) Each component has a distinct mechanism of action targeting cancer cells through cytotoxic or immunomodulatory effects. While combinations such as doxorubicin plus cyclophosphamide or regimens including 5-fluorouracil with doxorubicin and cyclophosphamide are established in oncology—especially for breast cancer—the specific four-drug combination with BCG is not standard or widely documented. The rationale for combining these agents would be to maximize anti-tumor efficacy by leveraging both direct cytotoxicity and immune-mediated mechanisms.

Other names

5-fluorouracil + Adriamycin + cyclophosphamide + BCG